Q2 2024 13F Holders as of 30 Jun 2024
-
Type / Class
-
Equity / Common Shares, no par value
-
Shares outstanding
-
805K
-
Number of holders
-
10
-
Total 13F shares, excl. options
-
440K
-
Shares change
-
-246K
-
Total reported value, excl. options
-
$117K
-
Value change
-
-$95.8K
-
Number of buys
-
4
-
Number of sells
-
-9
-
Price
-
$0.27
Significant Holders of InMed Pharmaceuticals Inc. - Common Shares, no par value (INM) as of Q2 2024
17 filings reported holding INM - InMed Pharmaceuticals Inc. - Common Shares, no par value as of Q2 2024.
InMed Pharmaceuticals Inc. - Common Shares, no par value (INM) has 10 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 440K shares
of 805K outstanding shares and own 54.72% of the company stock.
Largest 10 shareholders include SABBY MANAGEMENT, LLC (307K shares), Virtu Financial LLC (86.7K shares), XTX Topco Ltd (17.8K shares), HRT FINANCIAL LP (16K shares), CITADEL ADVISORS LLC (12.1K shares), Qube Research & Technologies Ltd (200 shares), BANK OF AMERICA CORP /DE/ (100 shares), TD Waterhouse Canada Inc. (85 shares), AllSquare Wealth Management LLC (21 shares), and Global Retirement Partners, LLC (6 shares).
This table shows the top 10 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.